Ohm Laboratories Inc, a wholly-owned subsidiary of Ranbaxy has received approval from the US Food and Drug Administration for manufacturing and marketing Valsartan tablets in strengths of 40 mg, 80 mg, 160 mg, and 320 mg on an exclusive basis, Ranbaxy Laboratories said in a statement.
"The Office of Generic Drugs, USFDA, has determined the Ohm formulation to be bio-equivalent and have the same therapeutic effect as that of the branded drug Diovan," it added.
According to IMS-MAT sales data for April 2014, the total annual market sales for Diovan stood at $2.19
Sensex gains over 100 points; Ranbaxy at 52-week high
Indian, US generic cos launch 'Coalition for Affordable Care'
Policy tweaks in US shift Indian pharma's focus
Pharma M&As to drive Infosys' life sciences biz
FDA raises concern over US unit: Wockhardt